WCPO: After 35 years of surviving HIV and AIDS, Carl Fox is part of a study he believes will find a cure
Fox is part of UC's Trailblazer study
Carl Fox of Northern Kentucky found out he was HIV positive in 1985. After decades of living with the virus and watching the deaths of hundreds of friends, he joined a federally funded study and is allowing WCPO-TV to tell his story.
Carl Fichtenbaum, MD, of the UC Division of Infectious Diseases. Photo/Colleen Kelley/UC Creative + Brand
The TRAILBLAZER study, as it’s called, aims to change the parts of a patient’s white blood cells that HIV latches onto, says Carl Fichtenbaum, MD, professor in the Division of Infectious Diseases at the UC College of Medicine.
Fichtenbaum is a principal investigator on the study and has been Fox’s doctor for years.
“The idea behind this study that we’re doing is to take a person’s cells from their white blood cells that harbor that receptor, take it in the laboratory, remove the receptor through genetic engineering and then infuse those cells back into the person,” he tells WCPO.
“Our hope in the future is that perhaps if we were to do this often enough, and change enough cells in the body, that people who have HIV may be able to control the HIV, even without any medication,” Fichtenbaum says. “And it may be the first steps or ideas to really trying to cure people.”
See the full WCPO study here and read more about the TRAILBLAZER study here.
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's medical, graduate and undergraduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
The Last Show with David Cooper discusses AI in education with UC’s Joshua Lambert
April 12, 2026
The Last Show with David Cooper, a global news podcast, featured Joshua Lambert, PhD, a professor and biostatistician in UC College of Nursing to discuss his latest research on using artificial intelligence for student advising.
UC enrolls first patients in clinical trial for prosthetic joint infections
April 10, 2026
The University of Cincinnati has enrolled the first patients in Peptilogics’ RETAIN clinical trial, testing an investigational drug for prosthetic joint infections after total knee replacement to reduce repeat surgeries and infection recurrence.
Long before machine guns, ancient Romans used this rapid-fire weapon
April 9, 2026
Smithsonian highlights research by UC Classics Professor Steven Ellis, who supervised archaeological work in the Porta Stabia neighborhood of Pompeii.